170.14MMarket Cap-1.74P/E (TTM)
3.500High3.200Low1.16MVolume3.390Open3.610Pre Close3.89MTurnover4.33%Turnover RatioLossP/E (Static)50.04MShares6.71052wk High5.54P/B91.01MFloat Cap3.07552wk Low--Dividend TTM26.77MShs Float18.170Historical High--Div YieldTTM8.31%Amplitude2.440Historical Low3.360Avg Price1Lot Size
scPharmaceuticals Stock Forum
ScPharmaceuticals Inc - Observes Variability in Scp-111 Product Testing
Snda Submission for Scp-111 May Be Delayed
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication in Heart Failure
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals Inc. (SCPH) has secured non-dilutive financings totaling up to $125 million with Perceptive Advisors. The deal includes a $75 million senior secured loan and a $50 million revenue interest financing. Key benefits include:
1. Refinancing of existing debt with improved terms
2. Lower interest rate and extended interest-only period
3. Reduc...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
No comment yet